Orforglipron
Phase 3Completed 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Type 2 Diabetes
Conditions
Type 2 Diabetes
Trial Timeline
Sep 28, 2023 โ Jun 5, 2025
NCT ID
NCT06010004About Orforglipron
Orforglipron is a phase 3 stage product being developed by Eli Lilly for Type 2 Diabetes. The current trial status is completed. This product is registered under clinical trial identifier NCT06010004. Target conditions include Type 2 Diabetes.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06692348 | Phase 1 | Completed |
| NCT06440980 | Phase 1 | Completed |
| NCT06010004 | Phase 3 | Completed |
Competing Products
20 competing products in Type 2 Diabetes